Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,203 people get MDVN articles and Market Currents by email alert.
Get email alerts on MDVN »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
Medivation Loses A Major Patent Dispute; A Blow To The StockPropThink • Mon, Dec 24, 2012
-
-
-
-
-
Encouraging Data Sends Medivation SoaringThe Burrill Report • Mon, Nov 7, 2011 -
-
Medivation: The Most Promising Upcoming Prostate Cancer TreatmentTheMarketFinancial • Tue, Mar 29, 2011 -
Medivation Narrows LossZacks Investment Research • Wed, Aug 11, 2010
-
Medivation Reports Wider Q4 LossZacks Investment Research • Wed, Mar 17, 2010
-
-
-
Cause for Optimism from Medivation's Prostate Cancer DrugDouglas Krohn • Tue, Mar 4, 2008 -
-
Medivation: Progressing On Its Own TimeHilary Kramer • Tue, Mar 13, 2007
-
-
-
-
-
-
-
-
-
-
-
Astellas Needs To Pick A Model To ProsperStephen Simpson • Thu, Feb 21
-
-
-
-
-
Therapeutic Proteins Offer New Investment OpportunitiesCris Frangold • Sat, Nov 24, 2012 -
7 Biotech Stocks Trading At Steep Discount To Target PriceKapitall • Thu, Nov 15, 2012 -
-
-
-
Medivation Management Discusses Q2 2012 Results - Earnings Call TranscriptFri, Aug 10, 2012 • 1 Comment
-
Medivation CEO Discusses Q3 2010 Results - Earnings Call TranscriptFri, Nov 5, 2010
-
Medivation, Inc. Q2 2010 Earnings Call TranscriptMon, Aug 9, 2010
-
Medivation, Inc. Q1 2010 Earnings Call TranscriptMon, May 10, 2010
-
Medivation, Inc. Q4 2008 Earnings Call TranscriptMon, Mar 16, 2009
-
Medivation Inc. Q3 2008 Earnings Call TranscriptTue, Nov 11, 2008
-
Medivation, Inc. Q2 2008 Earnings Call TranscriptWed, Sep 3, 2008
-
Medivation, Inc. Q1 2008 Earnings Call TranscriptFri, May 23, 2008
-
Marketwire (Tue, 7:00AM)
-
at CNBC.com (Mon, 12:50PM)
-
Marketwire (May 13, 2013)
-
Marketwire (May 9, 2013)
-
Marketwire (May 6, 2013)
-
Marketwire (Apr 29, 2013)
-
Marketwire (Apr 25, 2013)
-
Marketwire (Apr 23, 2013)
-
Marketwire (Apr 1, 2013)
-
Marketwire (Mar 6, 2013)
-
Marketwire (Feb 28, 2013)
-
Marketwire (Feb 13, 2013)
-
Marketwire (Feb 6, 2013)
-
Marketwire (Feb 4, 2013)
-
Marketwire (Jan 30, 2013)
-
Marketwire (Nov 29, 2012)
-
Marketwire (Nov 9, 2012)
-
Marketwire (Nov 7, 2012)
MDVN vs. ETF Alternatives
Company Description
Currently, there's no company description for MDVN.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, June 17, 1:08 PM Xtandi competitor ARN-509 "still has many outstanding questions/hurdles," JPMorgan's Geoff Meacham says, reiterating an Overweight rating on shares of Medivation (MDVN -9.3%) which are currently in a tailspin following JNJ's acquisition of Aragon (I, II). Meacham acknowledges that Aragon's cause (both from a legal and development perspective) will be helped by JNJ's substantial resources, but notes that early stage prostate cancer agents face "significant clinical, regulatory, and commercial hurdles." Comment! [Healthcare, On the Move]
- Monday, June 17, 9:15 AM Shares of Medivation (MDVN) fall 6% premarket. Likely weighing on shares is Johnson & Johnson's acquisition of Aragon, whose prostate cancer drug ARN-509 was the subject of a lawsuit MDVN filed claiming rights to the compound. Comment! [Healthcare, On the Move]
-
Monday, June 17, 9:11 AM
Premarket gainers: OSH +47%. FRO +21%. KNDI +16%. LDK +8%. MNKD +5%. AMD +5%. DVAX +5%. NFLX +5%.
Losers: FOLD -29%. TEX -14%. MDVN -7%. Comment! [On the Move] - Monday, June 3, 8:06 AM Health Canada approves Medivation (MDVN) and Astellas' (ALPMY.PK) XTANDI (enzalutamide) for the treatment of metastatic castration-resistant prostate cancer. (Previous: XTANDI submitted to Japanese regulators; XTANDI sales rise) Comment! [Healthcare]
- Friday, May 24, 7:58 AM Astellas (ALPMY.PK) and Medivation (MDVN) say a marketing approval application for enzalutamide (its friends call it XTANDI and it's FDA approved) has been submitted to Japan's Ministry of Health, Labour, and Welfare for the treatment of prostate cancer. (PR) Comment! [Healthcare]
- Thursday, May 9, 5:27 PM More on Medivation (MDVN): Q1 beats on all fronts as per share losses came down and revenue went up. Net sales of Xtandi, as reported by partner Astellas, were $75.4M, a threefold increase over the prior quarter. The company says it continues to expect total operating expenses for 2013 to be between $285M and $300M. Shares -1% AH. Comment! [Healthcare, Earnings]
- Thursday, May 9, 4:13 PM Medivation (MDVN): Q1 EPS of -$0.36 beats by $0.02. Revenue of $46.15M beats by $7.61M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, May 9, 12:10 AM Notable earnings after Thursday’s close: AGO, AIRM, AL, ALIM, ANAC, ASYS, AUQ, BCEI, BID, BPZ, CALL, CPE, DAR, EGY, ET, FTK, FXEN, GXP, KTOS, LLNW, MBI, MCP, MDRX, MDVN, NGVC, NVDA, OPTR, PANL, PCLN, PDLI, PSA, RNDY, SF, SLXP, SQNM, TNGO, UBNT, ZGNX Comment! [Earnings]
- Wednesday, May 8, 5:35 PM Notable earnings after Thursday’s close: AGO, AIRM, AL, ALIM, ANAC, ASYS, AUQ, BCEI, BID, BPZ, CALL, CPE, DAR, EGY, ET, FTK, FXEN, GXP, KTOS, LLNW, MBI, MCP, MDRX, MDVN, NGVC, NVDA, OPTR, PANL, PCLN, PDLI, PSA, RNDY, SF, SLXP, SQNM, TNGO, UBNT, ZGNX Comment! [Earnings]
- Friday, April 26, 11:12 AM Medivation (MDVN +0.6%) and Astellas Pharma (ALPMF.PK) say the Committee for Medicinal Products for Human Use (CHMP) has recommended approval for the oral androgen receptor inhibitor XTANDI (approved in the U.S.) for adult men with progressed metastatic castration-resistant prostate cancer. Other CHMP news: Pfizer's (PFE -1.1%) arthritis pill Xeljanz is rejected (appeal to come), Roche (RHHBY.OB +0.2%) and Curis' (CRIS +4.5%) Erivedge for basal cell carcinoma gets a recommendation, and Vivus' (VVUS +3.7%) ED drug Spedra gets a positive review. (See also: AVNR and CELG get thumbs up from EU regulators) 1 Comment [Healthcare, On the Move]
- Thursday, April 4, 4:45 AM The cost of caring for people with dementia is $157-215B a year and could double by 2040, a study from RAND Corp. estimates. The cost of dementia treatment is $109B - above the $102B spent on heart disease and the $77B on cancer - with the other dementia expenses used for long-term day-to-day care. Companies that develop drugs for Alzheimer's disease and other conditions include Pfizer (PFE), Eli Lilly (LLY), J&J (JNJ) and Merck (MRK). 5 Comments [Healthcare]
- Wednesday, March 6, 8:51 AM SA Author Amit Cohen of Biomed Group delves into the strong initial sales of Medivation's (MDVN) Xtandi treatment for prostate cancer, which was launched in the U.S. in September. Q4 revenues of the drug were $57.4M, while those of J&J's (JNJ) rival product Zytiga fell 16% sequentially. Although Xtandi is more expensive, it has a "number of advantages" over Zytiga. Comment! [Healthcare, Quick Ideas]
- Friday, March 1, 2:07 PM Medivation (MDVN -7%) slides today, despite posting a better than expected Q4 result yesterday. Collaboration revenue was $37.2M, more than the $34.4M in Q4 revenue analysts had expected. For FY13 the company expects operating expenses net of cost-sharing payments from Astellas, to be between $285M and $300M, approximately $29M of which consists of non-cash stock-based compensation expense. The company continues to expect approximately $7M in capital expenditures in 2013. Comment! [Healthcare, Earnings, On the Move]
- Thursday, February 28, 4:15 PM Medivation (MDVN): Q4 EPS of -$0.43 beats by $0.09. Revenue of $57.4M beats by $23.04M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, February 28, 12:10 AM Notable earnings after Thursday’s close: AIRM, AL, ALSK, BID, CLNE, CPNO, CRM, DECK, DRH, ENDP, GPS, GXP, HTGC, JOE, KOG, KYAK, MCP, MDR, MDVN, MENT, MTZ, MXWL, NGD, NOG, OPTR, OVTI, PANW, RNDY, RST, SD, SLXP, SONS, SPLK, SSRI, TEG, TESO, UHS, WR, XTEX, YOKU Comment! [Earnings]
- Wednesday, February 27, 5:35 PM Notable earnings after Thursday’s close: AIRM, AL, ALSK, BID, CLNE, CPNO, CRM, DECK, DRH, ENDP, GPS, GXP, HTGC, JOE, KOG, KYAK, MCP, MDR, MDVN, MENT, MTZ, MXWL, NGD, NOG, OPTR, OVTI, PANW, RNDY, RST, SD, SLXP, SONS, SPLK, SSRI, TEG, TESO, UHS, WR, XTEX, YOKU 1 Comment [Earnings]
-
- View all 0 replies
-
Poonam A. Arora
$MDVN Based on my analysis Xtandi revenues this year will beat analyst consensus of $213 million. - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
richarddamm
$MDVN is an interesting proposition for ultimately the success or failure of this or any other drug is efficacy. It is not working. - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 3 replies
-
-
-
- View all 0 replies
LATEST REPLIES
-
- View all 3 replies
-
-
-
- View all 2 replies
-
-
-
- View all 1 replies
-
-
The Scientist
MDVN MDV3100 studies are going to show it works even better in early stage prostate CA. All prostate CA patients will use MDV3100. - View all 1 replies
-
The Scientist: MDVN MDV3100 is going to be the standard of care for all prostate CA pts. All other drugs will be compared to MDV3100. Easily $5B + sales.
-
- View all 2 replies
-
-